Sino Biopharmaceutical financials at a glance
| Year | Year | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rev. | Revenue |
|
HK$664.30M | HK$756.07M | HK$734.65M | HK$1.16B | HK$2.28B | HK$3.23B | HK$4.09B | HK$5.78B | HK$7.50B | HK$9.90B | HK$12.38B | HK$14.55B | HK$13.54B | HK$14.82B | HK$20.89B | HK$24.23B | HK$23.65B | HK$26.86B | HK$28.78B | HK$0.00M | HK$0.00M |
| GM % | Gross Margin % |
|
79.95% | 81.56% | 81.11% | 82.33% | 79.26% | 80.23% | 80.79% | 78.50% | 78.52% | 77.49% | 76.41% | 77.67% | 79.20% | 79.14% | 79.91% | 79.67% | 78.08% | 80.15% | 79.86% | 0.00% | 0.00% |
| OM | Operating Margin |
|
21.45% | 20.23% | 15.67% | 21.16% | 22.54% | 22.86% | 20.84% | 15.67% | 18.05% | 17.29% | 17.89% | 19.29% | 20.00% | 21.74% | 19.73% | 20.00% | 17.33% | 15.74% | 20.43% | 0.00% | 0.00% |
| EPS | Earnings Per Share |
|
HK$0.11 | HK$0.01 | HK$0.01 | HK$0.02 | HK$0.02 | HK$0.03 | HK$0.03 | HK$0.04 | HK$0.05 | HK$0.07 | HK$0.13 | HK$0.11 | HK$0.12 | HK$0.15 | HK$0.17 | HK$0.17 | HK$0.73 | HK$0.12 | HK$0.16 | HK$0.00 | |
| Div. | Dividends |
|
HK$0.01 | HK$0.00 | HK$0.01 | HK$0.01 | HK$0.01 | HK$0.01 | HK$0.02 | HK$0.02 | HK$0.01 | HK$0.01 | HK$0.01 | HK$0.01 | HK$0.02 | HK$0.03 | HK$0.05 | HK$0.05 | HK$0.07 | HK$0.06 | HK$0.11 | HK$0.06 | HK$0.00 |
| PR % | Payout Ratio % |
|
50.00% | 0.00% | 100.00% | 100.00% | 50.00% | 50.00% | 66.67% | 66.67% | 25.00% | 20.00% | 14.29% | 7.69% | 18.18% | 25.00% | 33.33% | 29.41% | 41.18% | 8.22% | 91.67% | 37.50% | 0 |
| Sha. | Shares |
|
13446.15m | 15281.95m | 15281.95m | 15281.95m | 15281.95m | 15281.79m | 16728.68m | 16677.43m | 16677.43m | 16677.43m | 16677.43m | 16677.43m | 16677.43m | 16677.43m | 18883.8m | 18810.96m | 18,790m | 18756.11m | 18481.25m | 18399.24m | 0m |
| OCF | Operating Cash Flow |
|
HK$255.22M | HK$263.73M | HK$119.73M | HK$252.48M | HK$415.55M | HK$686.69M | HK$502.67M | HK$1.09B | HK$1.36B | HK$1.58B | HK$2.30B | HK$2.29B | HK$2.99B | HK$3.73B | HK$5.09B | HK$5.32B | HK$5.33B | HK$5.37B | HK$6.27B | HK$0.00M | HK$0.00M |
| FCF | Free Cash Flow |
|
HK$142.00M | HK$193.23M | HK$65.87M | HK$179.03M | HK$224.49M | HK$346.30M | HK$140.96M | HK$657.41M | HK$957.98M | HK$865.20M | HK$1.33B | HK$1.25B | HK$2.25B | HK$2.67B | HK$3.40B | HK$3.18B | HK$3.74B | HK$3.81B | HK$4.51B | HK$4.79B | HK$0.00M |
| FCFS | Free Cash Flow Per Share |
|
HK$0.01 | HK$0.01 | HK$0.00 | HK$0.01 | HK$0.01 | HK$0.02 | HK$0.01 | HK$0.05 | HK$0.06 | HK$0.06 | HK$0.11 | HK$0.06 | HK$0.13 | HK$0.16 | HK$0.18 | HK$0.19 | HK$0.19 | HK$0.19 | HK$0.25 | HK$0.00 | HK$0.00 |